Hepatitis B virus reactivation (HBVr) is emerging as an important clinical entity, with the
advent of highly potent immunosuppression licensed for use as the treatment of a widening
range of clinical indications. HBVr can lead to severe acute liver failure and death. Risk can
be minimised through appropriate screening, monitoring and antiviral prophylaxis.
Screening for serological markers at the earliest opportunity is recommended. Risk
stratification should then be performed on the basis of characteristics of the underlying …